Findings

What do systematic reviews say?

7 questions · 7 findings · 1 reviews

Sort:Best matchNewest Highest certainty Download CSV

No studies found 2 · 28.6%GRADE not reported 0 · 0%Very low 0 · 0%Low 1 · 14.3%Moderate 4 · 57.1%High 0 · 0%

Summary of findings: tobramycin for inhalation powder vs tobramycin

FEV1 % predicted: relative change from baseline · adults and children with cystic fibrosis and a positive microbiological isolate of P aeruginosa from a respiratory tract specimen

1 finding from 1 review

Inhaled anti‐pseudomonal antibiotics for long‐term therapy in cystic fibrosis 2022 · Cochrane Headline outcomes only
no estimate extracted
1 study · 517 participants
Moderate

Summary of findings: tobramycin for inhalation powder vs tobramycin

FVC · adults and children with cystic fibrosis and a positive microbiological isolate of P aeruginosa from a respiratory tract specimen

The review found no eligible studies for this question.

1 finding from 1 review

Inhaled anti‐pseudomonal antibiotics for long‐term therapy in cystic fibrosis 2022 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Summary of findings: tobramycin for inhalation powder vs tobramycin

Exacerbations (number of people experiencing ≥ 1 exacerbations) · adults and children with cystic fibrosis and a positive microbiological isolate of P aeruginosa from a respiratory tract specimen

Summary of findings: tobramycin for inhalation powder showed no clear difference in pulmonary exacerbations: number of participants experiencing… compared with tobramycin (moderate certainty).

1 finding from 1 review

Inhaled anti‐pseudomonal antibiotics for long‐term therapy in cystic fibrosis 2022 · Cochrane Headline outcomes only
RR 1.12 [0.86, 1.45]
1 study · 517 participants
Moderate

Summary of findings: tobramycin for inhalation powder vs tobramycin

Quality of life · adults and children with cystic fibrosis and a positive microbiological isolate of P aeruginosa from a respiratory tract specimen

The review found no eligible studies for this question.

1 finding from 1 review

Inhaled anti‐pseudomonal antibiotics for long‐term therapy in cystic fibrosis 2022 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Summary of findings: tobramycin for inhalation powder vs tobramycin

Survival: number of deaths · adults and children with cystic fibrosis and a positive microbiological isolate of P aeruginosa from a respiratory tract specimen

1 finding from 1 review

Inhaled anti‐pseudomonal antibiotics for long‐term therapy in cystic fibrosis 2022 · Cochrane Headline outcomes only
4.76 [0.25, 91.62]
1 study · 517 participants
Low

Summary of findings: tobramycin for inhalation powder vs tobramycin

Antibiotic resistance: change from baseline in P aeruginosa CFU/g of sputum at week 24 · adults and children with cystic fibrosis and a positive microbiological isolate of P aeruginosa from a respiratory tract specimen

1 finding from 1 review

Inhaled anti‐pseudomonal antibiotics for long‐term therapy in cystic fibrosis 2022 · Cochrane Headline outcomes only
no estimate extracted
1 study · 517 participants
Moderate

Summary of findings: tobramycin for inhalation powder vs tobramycin

Adverse events: number of any adverse event reported · adults and children with cystic fibrosis and a positive microbiological isolate of P aeruginosa from a respiratory tract specimen

Summary of findings: tobramycin for inhalation powder showed no clear difference in adverse events: number of any adverse event reported compared with tobramycin (moderate certainty).

1 finding from 1 review

Inhaled anti‐pseudomonal antibiotics for long‐term therapy in cystic fibrosis 2022 · Cochrane Headline outcomes only
RR 1.07 [1, 1.15]
1 study · 517 participants
Moderate